|Articles|June 3, 2019

Novel compound shows promise for dry eye in proof-of-concept study

Topical drug for the treatment of dry eye disease sees potential 

Eric D. Donnenfeld, MD, FAAO, shares results from an ex-U.S. proof-of-concept study investigating a novel, small peptide anti-integrin topical therapy (ALG-1007, Allegro Ophthalmics) for the treatment of dry eye disease. He presented his research at the 2019 annual ASCRS meeting in San Diego.

RELATED: Sustained-release implant promising for long-term IOP reduction

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!

Related Content